Could a probiotic boost breast cancer treatment? new trial aims to find out
NCT ID NCT07552181
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will take MO-03 capsules twice daily until surgery, and the main goal is to see if the cancer completely disappears by the time of surgery. The study is not yet recruiting and will follow participants for five years after surgery to track cancer recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MO-03 (a live biotherapeutic product, a type of probiotic) taken as a capsule twice daily, plus standard pembrolizumab and chemotherapy
- What this could lead to
- If successful, this combination could improve the chance of eliminating all cancer before surgery, potentially reducing recurrence risk in early triple-negative breast cancer.
- What could go wrong
- This is a small, single-site Phase II trial with no control group, so results may not be definitive. The added benefit of MO-03 over standard therapy alone is uncertain, and side effects from the combination are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
CS Cancer at Valley Oncology Medical Group
Tarzana, California, 91356, United States
-
Cedars-Sinai Medical Center Beverly Hills
Beverly Hills, California, 90211, United States
-
Hunt Cancer Institute, an Affiliate of CS Cancer
Torrance, California, 90505, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors